In 2023, Werewolf Therapeutics, Inc. anticipated multiple catalysts as the company progress the company's two clinical stage programs, WTX-124 and WTX-330, through first in human testing and expect to share initial clinical data on the safety, tolerability, and preliminary efficacy of WTX-124 in the fourth quarter. Initial first-in-human clinical data for IL-2 INDUKINE WTX-124 monotherapy expected in fourth quarter of 2023 from Phase 1/1b clinical trial in advanced or metastatic solid tumor.